A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE- 826)

March 27, 2019
https://clinicaltrials.gov/ct2/show/NCT03635567
Cancer - Cervical
Principal Investigator: Rabbie K Hanna, MD

First-Line Treatment,

Persistent, Recurrent,  Metastatic,

Cervical Cancer,

KEYNOTE, 826,

Pembrolizumab, MK-3475

Open